Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATE study of risankizumab-800CW fluorescence imaging in inflammatory bowel disease
NL-OMON60097Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by University Medical Center Groningen. Primary endpoints: Safety of risankizumab-800CW and Feasibility of fluorescence detection. Started Nov 2024; status: completed.
02
Drugs
risankizumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON60097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60097.